In July 2011, Amgen announced that it received "complete response" letters from FDA regarding applications for panitumumab (Vectibix) in first-line and second-line metastatic colon cancer. "We are currently working to address their requests," the annual report states.
Amgen’s denosumab (Xgeva) failed to win approval for delaying or preventing bone metastases in prostate cancer, though it remains in late-stage development for a similar indication in breast cancer.
Editor’s note: This story appears courtesy of "The Pink Sheet," a weekly Elsevier publication covering pharmaceutical business and policy issues. To learn more, contact customer care at 800-332-2181 or sign up for a free trial.